Xenon Pharmaceuticals XENE EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Xenon Pharmaceuticals’s reported figures.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's EBITDA?
- Xenon Pharmaceuticals (XENE) reported EBITDA of -$111.74M in Q1 2026.
- How has Xenon Pharmaceuticals's EBITDA changed year-over-year?
- Xenon Pharmaceuticals's EBITDA decreased by 55.0% year-over-year, from -$72.08M to -$111.74M.
- What is the long-term trend for Xenon Pharmaceuticals's EBITDA?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's EBITDA has grown at a 68.0% compound annual growth rate (CAGR), from -$78.09M to -$370.53M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.